Lauren Pinter‐Brown
About
Lauren Pinter‐Brown is a scholar working on Pathology and Forensic Medicine, Oncology and Dermatology.
According to data from OpenAlex, Lauren Pinter‐Brown has authored 99 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Pathology and Forensic Medicine, 38 papers in Oncology and 37 papers in Dermatology. Recurrent topics in Lauren Pinter‐Brown's work include Lymphoma Diagnosis and Treatment (73 papers), Cutaneous lymphoproliferative disorders research (37 papers) and Chronic Lymphocytic Leukemia Research (27 papers). Lauren Pinter‐Brown is often cited by papers focused on Lymphoma Diagnosis and Treatment (73 papers), Cutaneous lymphoproliferative disorders research (37 papers) and Chronic Lymphocytic Leukemia Research (27 papers). Lauren Pinter‐Brown collaborates with scholars based in United States, France and Italy. Lauren Pinter‐Brown's co-authors include Andrei R. Shustov, Barbara Pro, Bertrand Coiffier, Francine M. Foss, Lubomir Sokol, Sarah McCue Horwitz, Madeleine Duvic, Nancy L. Bartlett, Swaminathan P. Iyer and Youn H. Kim and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Lauren Pinter‐Brown
98 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lauren Pinter‐Brown United States | 26 | 2.0k | 1.3k | 1.2k | 1.2k | 710 | 99 | 3.3k | ||
| Claudio Agostinelli Italy | 30 | 2.0k 1.0× | 1.5k 1.1× | 564 0.5× | 992 0.9× | 624 0.9× | 151 | 3.3k | ||
| Santiago Montes‐Moreno Spain | 34 | 2.0k 1.0× | 1.4k 1.1× | 535 0.4× | 670 0.6× | 628 0.9× | 102 | 3.0k | ||
| Jasmine Zain United States | 31 | 2.2k 1.1× | 1.7k 1.2× | 1.4k 1.1× | 1.4k 1.2× | 1.4k 2.0× | 184 | 4.3k | ||
| Kennosuke Karube Japan | 31 | 1.8k 0.9× | 1.3k 0.9× | 432 0.4× | 1.2k 1.1× | 550 0.8× | 136 | 3.2k | ||
| Andrei R. Shustov United States | 34 | 3.3k 1.7× | 2.5k 1.9× | 1.4k 1.2× | 2.0k 1.7× | 907 1.3× | 158 | 5.3k | ||
| Ryo Ichinohasama Japan | 26 | 1.6k 0.8× | 1.2k 0.9× | 392 0.3× | 472 0.4× | 716 1.0× | 154 | 2.9k | ||
| Luís Colomo Spain | 25 | 1.9k 1.0× | 1.6k 1.2× | 428 0.4× | 779 0.7× | 240 0.3× | 66 | 2.7k | ||
| Jacques Bosq France | 31 | 1.1k 0.6× | 1.2k 0.9× | 295 0.2× | 620 0.5× | 482 0.7× | 74 | 2.5k | ||
| Leonardo Flenghi Italy | 24 | 1.5k 0.7× | 876 0.7× | 346 0.3× | 975 0.8× | 536 0.8× | 36 | 2.7k | ||
| Lapo Alinari United States | 30 | 1.7k 0.9× | 793 0.6× | 442 0.4× | 518 0.4× | 623 0.9× | 115 | 2.8k |
Countries citing papers authored by Lauren Pinter‐Brown
Since
Specialization
Citations
This map shows the geographic impact of Lauren Pinter‐Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lauren Pinter‐Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lauren Pinter‐Brown more than expected).
Fields of papers citing papers by Lauren Pinter‐Brown
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lauren Pinter‐Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lauren Pinter‐Brown. The network helps show where Lauren Pinter‐Brown may publish in the future.
Co-authorship network of co-authors of Lauren Pinter‐Brown
This figure shows the co-authorship network connecting the top 25 collaborators of Lauren Pinter‐Brown. A scholar is included among the top collaborators of Lauren Pinter‐Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lauren Pinter‐Brown. Lauren Pinter‐Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zinzani, Pier Luigi, Eric D. Jacobsen, Jasmine Zain, et al.. (2024). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial. Blood. 144(Supplement 1). 3061–3061.
2.
Bennani, N. Nora, Aung M. Tun, Kenneth R. Carson, et al.. (2021). Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma Myeloma & Leukemia. 22(4). e250–e260.
3.
Anastasiadou, Eleni, Anita G. Seto, Xuan Beatty, et al.. (2020). Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clinical Cancer Research. 27(4). 1139–1149.
4.
Huen, Auris, Bradley M. Haverkos, Jasmine M. Zain, et al.. (2020). Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers. 12(8). 2293–2293.
5.
Lansigan, Frederick, Sarah McCue Horwitz, Lauren Pinter‐Brown, et al.. (2020). Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. Clinical Lymphoma Myeloma & Leukemia. 20(11). 744–748.
6.
Pinter‐Brown, Lauren, et al.. (2020). <p>Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection</p>. Drug Design Development and Therapy. Volume 14. 3747–3754.
7.
Evans, Mark G., Roberto N. Miranda, Patricia A. Young, et al.. (2020). B-cell lymphomas associated with breast implants: Report of three cases and review of the literature. Annals of Diagnostic Pathology. 46. 151512–151512.
8.
Oki, Yasuhiro, Jasmine Zain, Bradley M. Haverkos, et al.. (2017). Safety and Anti-Tumour Activity of RP6530, Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study. Blood. 130. 2791–2791.
9.
Advani, Ranjana H., Stephen M. Ansell, Mary Jo Lechowicz, et al.. (2015). A phase II study of cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( PTCL ): final results from the T‐ cell consortium trial. British Journal of Haematology. 172(4). 535–544.
10.
Horwitz, Sarah McCue, Bertrand Coiffier, Francine M. Foss, et al.. (2015). Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Annals of Oncology. 26(4). 774–779.
11.
Loh, John C., David S. Cassarino, Wayne W. Grody, Melvin Chiu, & Lauren Pinter‐Brown. (2014). A Case of Mycosis Fungoides Transmitted From Donor to Recipient, and Review of Literature of T-Cell Malignancies After Transplantation. Clinical Lymphoma Myeloma & Leukemia. 14(4). e137–e140.
12.
Coiffier, Bertrand, Barbara Pro, H. Miles Prince, et al.. (2012). Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. Journal of Clinical Oncology. 30(6). 631–636.
13.
Foss, Francine M., Sarah McCue Horwitz, Bertrand Coiffier, et al.. (2012). Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study. Clinical Lymphoma Myeloma & Leukemia. 12(4). 238–243.
14.
O’Connor, Owen A., Barbara Pro, Lauren Pinter‐Brown, et al.. (2011). Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. Journal of Clinical Oncology. 29(9). 1182–1189.
15.
Olsen, Elise A., Alain H. Rook, John A. Zic, et al.. (2010). Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal of the American Academy of Dermatology. 64(2). 352–404.
16.
Kim, Youn H., Michael Girardi, Madeleine Duvic, et al.. (2010). Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology. 63(6). 975–983.
17.
Bernengo, M.G., F. Vanaclocha, Madeleine Duvic, et al.. (2008). A Phase Ii International, Multicenter Study of Oral Panobinostat (lbh589) in Patients With Refractory Cutaneous T-cell Lymphoma (ctcl). DIAL (Catholic University of Leuven). 93. 109.
18.
Pinter‐Brown, Lauren. (2008). SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies. Expert Opinion on Investigational Drugs. 17(12). 1883–1887.
19.
Hu, Jenny, Parrish Sadeghi, Lauren Pinter‐Brown, Sharona Yashar, & Melvin Chiu. (2006). Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. Journal of the American Academy of Dermatology. 56(2). 317–326.
20.
Roberts, Alice, Maho Amano, Marisa Galvan, et al.. (2003). Galectin-1–Mediated Apoptosis in Mycosis Fungoides: The Roles of CD7 and Cell Surface Glycosylation. Modern Pathology. 16(6). 543–551.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Claudio Agostinelli Breakdown of academic impact, for papers by Santiago Montes‐Moreno Breakdown of academic impact, for papers by Jasmine Zain Breakdown of academic impact, for papers by Kennosuke Karube Breakdown of academic impact, for papers by Andrei R. Shustov Breakdown of academic impact, for papers by Ryo Ichinohasama Breakdown of academic impact, for papers by Luís Colomo Breakdown of academic impact, for papers by Jacques Bosq Breakdown of academic impact, for papers by Leonardo Flenghi Breakdown of academic impact, for papers by Lapo Alinari